

【HARRIER】

AMD

HARRIER C002 4⁵7⁸

4 20200027

5 20200028

7 Dugel PU, et al. Ophthalmology 2020;127:172-84. 20190561

COI 2

8

C002 20200012

48 6mg 2mg


50 ※1 choroidal neovascularization CNV 739

※1

- CNV 50
- intraretinal fluid IRF subretinal fluid SRF
- ETDRS early treatment diabetic retinopathy study 78 23

6mg 2mg 1 1 4 3
6mg 12 2mg 8 16 6mg 2mg
6mg 8

Image



※2 □□□□□□□□

1111

1111

16□

- 5mm
- 12mm 3mm 75µm
- 12mm 5mm
- 12mm/IRF

20□28□32□40□44□※³

- 12^a 5^a

52□56□64□68□ 76□80□88□92□※³

- 48^b 5

[illegible]

a 12 44 8

b)

48	44	2
----	----	---

□ □ □ □ □ □

□□□□□□□□※4□□□□□□□□□□□□□□48□□

□ □ □ □ □ □ □ □ □ □

□□□□□□□□※4□□□□□□□□□□□□□□□□□□□□36□48□□

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

- 12 48
- 12 48

[illegible]

- □□□□□□□□※4□□□□□□□□□□□□96□□□□□□□□

- 15mm² 84mm² 48mm² 96mm²
- 15mm² 48mm² 96mm²
- 12mm² 96mm²
- 12mm² 96mm²
- 16mm² 16mm²
- 36mm² 48mm²
- CNV 12mm² 48mm² 96mm²
- CNV 12mm² 48mm² 96mm²
- IRF SRF 16mm² 48mm² 96mm²
- sub-RPE fluid 16mm² 48mm² 96mm²

※4 ETDRS□□□□ETDRS□□□□□□□□□□□□4m□□□□

□ □ □ □ □ □ □

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

□□□□

[\[REDACTED\]](#)

[REDACTED]
FAS [REDACTED]
[REDACTED]1 [REDACTED]
[REDACTED]
[REDACTED]s5 [REDACTED]70 [REDACTED]71 [REDACTED]75 [REDACTED]75 [REDACTED]ANOVA [REDACTED]6mg [REDACTED]2mg [REDACTED]95 [REDACTED]4 [REDACTED]2mg [REDACTED]6mg [REDACTED]0.025 [REDACTED]LOCF last
observation carried forward [REDACTED]VEGF [REDACTED]
[REDACTED]
[REDACTED]

□ □ □ □ □ □ □ □ □ □ □ □ □ □

FAS FAS 12 Kaplan-Meier Confounding effect 8

□ □ □ □ □ □ □ □ □ □

[illegible][illegible]

Image

